Infliximab Trough Level Therapeutic Range

Interpret infliximab trough levels for Crohn's disease and ulcerative colitis: target ≥3–5 mg/L for remission, ≥7 mg/L for mucosal healing. Differentiate pharmacokinetic failure from pharmacodynamic failure.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Interpret infliximab trough levels for Crohn's disease and ulcerative colitis: target ≥3–5 mg/L for remission, ≥7 mg/L for mucosal healing. Differentiate pharmacokinetic failure from pharmacodynamic failure

Each component has a specific meaning:

  • Pharmacodynamic failure — The pharmacodynamic failure recorded for the scenario being assessed.

Note: Interpret the infliximab trough level result against the thresholds and context described above.

How to Use

Enter the pharmacodynamic failure for the scenario you are assessing. Interpret infliximab trough levels for Crohn's disease and ulcerative colitis: target ≥3–5 mg/L for remission, ≥7 mg/L for mucosal healing. Differentiate pharmacokinetic failure from pharmacodynamic failure. Use the infliximab trough level result to inform your calculation.

Frequently Asked Questions